Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14283239 | 0.98 | ALDH1A1 (0.70) | USP2ALDH1A1HSD17B10GAAHTT | |
| SCHEMBL13982817 | 0.95 | ALDH1A1 (0.65) | USP2ALDH1A1HSD17B10HTTLMNA | |
| SCHEMBL14094061 | 0.83 | L3MBTL1 (0.68) | ALDH1A1HSD17B10GAALMNAKMT2A | |
| SCHEMBL16809210 | 0.83 | MAPT (0.63) | USP2ALDH1A1MAPT | |
| SCHEMBL13982806 | 0.83 | USP2 (0.67) | USP2ALDH1A1HSD17B10GAAHTT | |
| SCHEMBL12793711 | 0.82 | USP2 (0.71) | USP2ALDH1A1HSD17B10GAAHTT | |
| SCHEMBL6945990 | 0.82 | USP2 (0.71) | USP2ALDH1A1HSD17B10GAAHTT | |
| SCHEMBL4655481 | 0.82 | USP2 (0.71) | USP2ALDH1A1HSD17B10GAAHTT | |
| SCHEMBL4070839 | 0.80 | ALDH1A1 (0.84) | USP2ALDH1A1GAAHTTLMNA | |
| SCHEMBL14057770 | 0.80 | KMT2A (0.51) | ALDH1A1HTTLMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020028482-A1 | SMALL MOLECULES THAT SENSITIZE HIV-1 INFECTED CELLS TO ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-02-06 | — | — | WO | disclosed |
| EP-2258356-B1 | CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES | CT INGENIERIA GENETICA BIOTECNOLOGIA (CU) | 2017-09-27 | — | — | EP | disclosed |
| CN-103384668-B | compounds and compositions for inhibition of NAMPT | 福马TM有限责任公司 | 2017-05-31 | — | — | CN | disclosed |
| US-8975399-B2 | Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF | VAX-CONSULTING (FR) | 2015-03-10 | — | — | US | disclosed |
| US-8975399-B2 | Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF | VAX-CONSULTING (FR) | 2015-03-10 | — | — | US | disclosed |
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | VAX-CONSULTING (FR) | 2013-05-16 | — | — | US | disclosed |
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | VAX-CONSULTING (FR) | 2013-05-16 | — | — | US | disclosed |
| EP-1673086-B1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR88 | USP2 3877/4885ALDH1A1 2125/4885HSD17B10 4462/4885 |
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | TNF, TNFRSF1A, TRAF6 | USP2 1074/4885ALDH1A1 205/4885HSD17B10 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.